Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
Last Updated: Monday, June 14, 2021
According to data from a recent study, among patients age 70 and older with diffuse large B-cell lymphoma receiving R-CHOP, those receiving a full dose (intended dose intensity [IDI] ≥80%) experienced a higher rate of infection-related hospitalization (33%) compared with those receiving an attenuated dose (IDI <80%; 23.3%; odds ratio 1.61 [95% CI, 1.15-2.25; P =.006]).
Advertisement
News & Literature Highlights
